


# VIS phase I: vaccine and disease parameters assessed

		Phase I Indicator
<b>Health impact</b>	Impact on child mortality	U5 future deaths averted, 2015 – 2030
	Impact on overall mortality	U5 future deaths averted per 100,000 vaccinated population
	Impact on overall morbidity	Total future deaths averted, 2015 – 2030 Total future deaths averted per 100,000 vaccinated population Total future cases averted, 2015 - 2030 Total future cases averted per 100,000 vaccinated population Long-term sequelae
<b>Additional impact considerations</b>	Epidemic potential	Epidemic potential of disease
	Global or regional public health priority	Presence of global / regional (UN) resolution on elimination or eradication
	Herd immunity	Herd immunity threshold
	Availability of alternative interventions	Current use of alternative interventions for effective disease control (prevention and treatment) and potential for scale up
	Socio-economic inequity	Disproportionate impact on poor
	Gender inequity	Disproportionate impact on one gender
<b>Implementation feasibility</b>	Disease of regional importance	Burden concentrated in a subset of GAVI countries within same region
	Capacity and supplier base	Capacity to meet GAVI demand and # of manufacturers by 2020
	GAVI market shaping potential	GAVI demand as % of global demand
	Ease of supply chain integration	Packed volume (cm3) compared to benchmarks
	Ease of programmatic integration	Alignment with other vaccine schedules and significant change in health worker practices/behavior required
<b>Cost and value for money</b>	Vaccine efficacy and safety	Vaccine efficacy (as defined by clinical endpoints) and safety (evidence of causal link with severe adverse events)
	Vaccine procurement cost	Total procurement cost to GAVI and countries, 2015 – 2030
	In-country operational cost	Incremental in-country operational cost per vaccinated person
	Procurement cost per event averted	Procurement cost per death / case averted

# VIS phase I: consultations identified 5 key criteria to drive first prioritization

Category	VIS Criteria
Health impact	Impact on child mortality
	Impact on overall mortality
	Impact on overall morbidity
Additional impact considerations	Epidemic potential
	Global or regional public health priority
	Herd immunity
	Availability of alternative interventions
	Socio-economic inequity
	Gender inequity
	Disease of regional importance
Implementation feasibility	Capacity and supplier base
	GAVI market shaping potential
	Ease of supply chain integration
	Ease of programmatic integration
	Vaccine efficacy and safety
Cost and value for money	Vaccine procurement cost
	In-country operational cost
	Procurement cost per event averted

- Health impact (mortality and morbidity) most important
- Also consider epidemic diseases and value for money
- Verify additional benefits and implementation feasibility



# VIS phase II: assessment framework for shortlisted vaccine investments

